Causes of death after fluid bolus resuscitation: new insights from FEAST

BMC Medicine

Simon Finfer²  John Myburgh¹ 

[1] St George Clinical School, University of New South Wales, The George Institute for Global Health, L13, 321 Kent Street, Sydney 2000, Australia;Royal North Shore Hospital, University of Sydney, The George Institute for Global Health, L13, 321 Kent Street, Sydney 2000, Australia

关键词: shock;    sepsis;    saline;    reperfusion injury;    pediatrics;    malaria;    fluid resuscitation;    FEAST trial;    cardiogenic shock;    albumin;   

Others  :  857150
DOI  :  10.1186/1741-7015-11-67

 received in 2013-02-14, accepted in 2013-03-14,  发布年份 2013

【 摘 要 】

The Fluid Expansion as Supportive Therapy (FEAST study) was an extremely well conducted study that gave unexpected results. The investigators had reported that febrile children with impaired perfusion treated in low-income countries without access to intensive care are more likely to die if they receive bolus resuscitation with albumin or saline compared with no bolus resuscitation at all. In a secondary analysis of the trial, published in BMC Medicine, the authors found that increased mortality was evident in patients who presented with clinical features of severe shock in isolation or in conjunction with features of respiratory or neurological failure. The cause of excess deaths was primarily refractory shock and not fluid overload. These features are consistent with a potential cardiotoxic or ischemia-reperfusion injury following resuscitation with boluses of intravenous fluid. Although these effects may have been amplified by the absence of invasive monitoring, mechanical ventilation or vasopressors, the results provide compelling insights into the effects of intravenous fluid resuscitation and potential adverse effects that extend beyond the initial resuscitation period. These data add to the increasing body of literature about the safety and efficacy of intravenous resuscitation fluids, which may be applicable to management of other populations of critically ill patients.

【 授权许可】

   
2013 Myburgh and Finfer; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Maitland K, Kiguli S, Opoka R, Engoru C, Olupot-Olupot P, Akech S, Nyeko R, Mtove G, Reyburn H, Lang T, Brent B, Evans JA, Tibenderana JK, Crawley J, Russell EC, Levin M, Babiker AG, Gibb DM, FEAST Trial Group: Mortality after fluid bolus in African children with shock. N Engl J Med 2011, 364:2483-2495.
• [2]Duke T: What the African fluid-bolus trial means. Lancet 2011, 378:1685-1687.
• [3]Southall DP, Samuels MP: Treating the wrong children with fluids will cause harm: response to 'mortality after fluid bolus in African children with severe infection'. Arch Dis Child 2011, 96:905-906.
• [4]Maitland K, George E, Evans J, Kiguli S, Olupot-Olupot P, Akech S, et al.: Exploring mechanisms of excess mortality with early fluid resuscitation: insights from the FEAST trial. BMC Medicine 2013, 11:68. BioMed Central Full Text
• [5]Funk DJ, Jacobsohn E, Kumar A: The role of venous return in critical illness and shock-part I: physiology. Crit Care Med 2013, 41:250-257.
• [6]Persichini R, Silva S, Teboul JL, Jozwiak M, Chemla D, Richard C, Monnet X: Effects of norepinephrine on mean systemic pressure and venous return in human septic shock. Crit Care Med 2012, 40:3146-3153.
• [7]Bellomo R, Morimatsu H, French C, Cole L, Story D, Uchino S, Naka T, SAFE Study Investigators: The effects of saline or albumin resuscitation on acid-base status and serum electrolytes. Crit Care Med 2006, 34:2891-2897.
• [8]Morgan TJ, Vellaichamy M, Cowley DM, Weier SL, Venkatesh B, Jones MA: Equivalent metabolic acidosis with four colloids and saline on ex vivo haemodilution. Anaesth Intensive Care 2009, 37:407-414.
• [9]Langer T, Carlesso E, Protti A, Monti M, Comini B, Zani L, Andreis DT, Iapichino GE, Dondossola D, Caironi P, Gatti S, Gattinoni L: In vivo conditioning of acid-base equilibrium by crystalloid solutions: an experimental study on pigs. Intensive Care Med 2012, 38:686-693.
• [10]SAFE Study Investigators: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004, 350:2247-2256.
• [11]Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA, CHEST Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group: Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012, 367:1901-1911.
• [12]Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, Madsen KR, Møller MH, Elkjær JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Søe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjældgaard AL, Fabritius ML, Mondrup F, Pott FC, Møller TP, et al.: Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012, 367:124-134.
• [13]SAFE Study Investigators: Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007, 357:874-884.
• [14]Cooper DJ, Myburgh J, Finfer S, Heritier S, Bellomo R, Billot L, Murray L, Vallance S: Albumin resuscitation for traumatic brain injury: is intracranial hypertension the cause of increased mortality? J Neurotrauma 2012, in press.